000 01292 a2200325 4500
005 20250517084152.0
264 0 _c20170126
008 201701s 0 0 eng d
022 _a1469-0691
024 7 _a10.1016/j.cmi.2016.02.012
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGiacobbe, D R
245 0 0 _aIs initial serum (1,3)-β-d-glucan truly associated with mortality in patients with candidaemia? Authors' response.
_h[electronic resource]
260 _bClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
_cJun 2016
300 _a579 p.
_bdigital
500 _aPublication Type: Letter
650 0 4 _aCandidemia
_xdiagnosis
650 0 4 _aHumans
650 0 4 _aPrognosis
650 0 4 _aProteoglycans
650 0 4 _aSerum
_xchemistry
650 0 4 _aSurvival Analysis
650 0 4 _abeta-Glucans
_xblood
700 1 _aViscoli, C
700 1 _aFurfaro, E
700 1 _aColombo, A L
700 1 _aDel Bono, V
773 0 _tClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
_gvol. 22
_gno. 6
_gp. 579
856 4 0 _uhttps://doi.org/10.1016/j.cmi.2016.02.012
_zAvailable from publisher's website
999 _c25820954
_d25820954